The function and composition of B cells in patients with Glioblastoma treated with and without Dexamethasone

The function and composition of B cells in patients with Glioblastoma treated with and without Dexamethasone - GBMdexaB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49155

Enrollment

Registered

2020-01-30

Start date

2020-03-06

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor Glioblastoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. MRI scan and patient history highly suspicious for a high grade glioma/glioblastoma 2. Indication for surgery as determined by the Multidisciplinairy Brain tumor Board 3. Patients are 18 years or older at first diagnosis 4. Patients are willing and able to give written informed consent

Exclusion criteria

Exclusion criteria: 1. No indication for surgery to confirm radiological diagnosis 2. Not able or willing to give informed consent 3. Allergy or intolerance to dexamethasone 4. Diagnosis of glioblastoma could not be confirmed by histological examination

Design outcomes

Primary

Measure	Time frame
In order to quantify and characterize atypic B cells, we have designed a B cell focused panel for analysis by means of mass cytometry that includes the following markers: CD45, CD49d, CD19, CD5, CCR5, CD7, IgD, CD20, IgA, CD25, CD86, CD123, CD21, CD45RA, CD14, CD27, CXCR3, CCR4, CD22, CTLA-4, CD79b, CD95Fas, CD45RO, CD44, CD38, CD73, CD24, CD3, CD9, IgM, HLA-DR, CD71, CD127, and CD16. Data acquisition and analysis will proceed as previously reported (Dusoswa et al., 2019). In addition to this, we will use a smaller panel containing a selection of the markers above with the addition of intracellular IL-10, as reported by others (Wiest et al., 2019).	—

Measure

Time frame

In order to quantify and characterize atypic B cells, we have designed a B cell focused panel for analysis by means of mass cytometry that includes the following markers: CD45, CD49d, CD19, CD5, CCR5, CD7, IgD, CD20, IgA, CD25, CD86, CD123, CD21, CD45RA, CD14, CD27, CXCR3, CCR4, CD22, CTLA-4, CD79b, CD95Fas, CD45RO, CD44, CD38, CD73, CD24, CD3, CD9, IgM, HLA-DR, CD71, CD127, and CD16. Data acquisition and analysis will proceed as previously reported (Dusoswa et al., 2019). In addition to this, we will use a smaller panel containing a selection of the markers above with the addition of intracellular IL-10, as reported by others (Wiest et al., 2019).

—

Secondary

Measure	Time frame
We will collect information regarding potential confounding factors, such as tumor volume, age, body weight, smoking, and other co-morbidities.	—

Countries

Netherlands

Outcome results